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We read the interesting results of Sperl et al. [1], reporting the
beneﬁts associated with analogues treatment of HBV-infected
kidney recipients (KR), which corroborate our previous ﬁndings
[2]. A signiﬁcant increase in graft and patient survival was
observed in both our studies, by comparison with series where
analogues were either not available [3,4] or less potent, with viral
resistance concerns [5].
These results are in concordance with the recent updated
european guidelines [6] which recommend HBV screening for
all patients with end-stage renal disease, candidates to renal
transplantation, and analogue as pre-emptive treatment prior
to transplantation, to reduce the risks of HBV reactivation, cirrho-
sis and hepatocellular carcinoma (HCC).
In our study, HCC was responsible for mortality in half of the
cases despite an efﬁcient viral suppression in patients with cir-
rhosis, but with less advanced ﬁbrosis (Metavir F2). This evi-
dences the need of regular ultrasound assessment for HCC early
detection, even if a complete viral suppression is fully achieved.
We speculate that in the future, the use of potent oral antivi-
rals, which do not enhance the risk of graft rejection in hepatitis C
virus (HCV)-infected kidney transplant recipients, will result in
the same beneﬁt, given the harmful impact of HCV infection of
the liver (cirrhosis and HCC), but also of the renal allograft (de
novo glomerulonephritis), on morbidity and mortality.
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